OPDIVO + YERVOY is manufactured by Bristol Myers Squibb. As advertised "OPDIVO + YERVOY works by helping your immune system to fight cancer. It does this by combining 2 immunotherapy medications that work in different but complementary ways."
According to Google:
"How much longer can you live with Opdivo and Yervoy?"
"In addition, the Opdivo plus Yervoy combination demonstrated a 6.5-year progression-free survival (PFS) rate of 34% (median of 11.5 months) while PFS rates were 29% (median of 6.9 months) and 7% (median of 2.9 months) for Opdivo alone and Yervoy alone, respectively." I believe this is when compared to Chemotherapy alone.
Let's see if the PFS rate will be improved by the addition of ZEN-3694 in the mix. How much BM Squibb would be willing to pay for ZEN-3694 if it meets its Clinical Trial primary objective?
Koo
